

## Researcher Information Form

**Name:** Lisa Privette Vinnedge

**Department/Division/College:**

(1) Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Department of Pediatrics and  
(2) Cancer and Cell Biology Program; University of Cincinnati College of Medicine

**Room/Address:**

T7.486 T Building, Cincinnati Children's Hospital, MLC 7018

**Phone:** 513-636-1155

**Email:** Lisa.Privette@cchmc.org

**Research Interest** (1-2 Sentences): My lab primarily focuses on the cellular and molecular mechanisms roles of the chromatin remodeling DEK protein in mammary gland biology and breast cancer progression. Additional areas of research in my lab include studying the role of DEK in myeloid disease, including acute myeloid leukemia, identifying novel blood biomarkers of cancer, and conducting pre-clinical testing of potential new cancer therapies.

**Unique Resources/Techniques:** 3D organoid culture, genetic and xenograft mouse models of breast cancer, histology and mammary gland whole mounts

**Representative Publications** (5 Maximum, May use Hyperlink):

Modur V, Singh N, Mohanty V, Chung E, Muhammad B, Choi K, Chen X, Chetal K, Ratner N, Salomonis N, Weirauch MT, Waltz S, Huang G, Privette-Vinnedge L, Park JS, Janssen EM, Komurov K., "Defective transcription elongation in a subset of cancers confers immunotherapy resistance," *Nature Communications*. 2018 Oct 23;9(1):4410. PMID: 30353012

Wise-Draper, T., Sendilnathan, A., Palackdharry, S., Pease, N.A., Qualtieri, J., Butler, R., Hashemi Sadraei, N., Morris, J.C., Patil, Y., Wilson, K., Mark, J., Casper, K., Takiar, V., Lane, A., Privette Vinnedge, L.M., "Decreased plasma DEK oncogene levels correlate with p16-negative disease and advanced tumor stage in a case-control study of patients with head and neck squamous cell carcinoma," *Translational Oncology*, 2018 Feb;11(1):168-174. PMID: 29289845

Privette Vinnedge, L.M., Benight, N.M., Wagh, P.K., Pease, N.A., Nashu, M.A., Serrano-Lopez, J., Adams, A.K., Cancelas, J.A., Waltz, S.E., Wells, S.I., "The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers," *Oncogene*, 2015 Apr 30;34(18):2325-36. Epub 2014 June 23, PMID: PMC4275425 =

Privette Vinnedge, L.M., Ho, S-M, Wikenheiser-Brokamp, K.A., Wells, S.I., "The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer," *PLoS One*, 2012;7(10):e46985; Epub 2012 Oct 10, PMID: PMC3468546 \* Top 25% of cited articles from *PLoS One*

Privette, L.M., Gonzalez, M.E., Ding, L., Kleer, C.G., Petty, E.M., "Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression," *Cancer Research*, 2007 Jul 1; 67(13):6064-74. Epub 2007 Jun 27, PMID: 17596595